尤瑞克林联合巴曲酶治疗进展性脑梗死的临床观察

Effects of urinary kallidinogenase combined with batroxobin on acute cerebral infarction patients

目的：研究尤瑞克林联合巴曲酶治疗进展性脑梗死的疗效及安全性。方法进展性脑梗死患者96例，按随机数字表随机分为两组，每组48例。对照组除常规治疗外，隔日应用1次巴曲酶（10 U、5 U、5 U），治疗组在对照组基础上应用尤瑞克林0.15 PNA 单位加入生理盐水100 ml 静脉滴注（约40滴/ min），连用14 d。观察治疗前及用药7 d、14 d 及28 d 后神经功能缺损（NIHSS 评分）及实验室指标变化。结果治疗组和对照组比较总有效率显著提高（P 〈0.05），治疗前后两组均无明显的不良反应。结论尤瑞克林联合巴曲酶治疗进展性脑梗死安全有效，值得临床推广。

Objective To study the effects and adverse reactions of urinary kallidinogenase （UK）combined with batroxobin on acute cerebral infarction. Methods The 96 patients with acute cer-ebral infarction were randomly divided into urinary kallidinogenase group and control group,with 48 pa-tients in each group. The patients in control group were given conventional treatment and batroxobin （10U,5U）every two days,and the patients in treatment group were additionly given UK（0. 15 PNA） added to saline solution 100 ml for intravenous drip,for 14 days. Effects were judged according to the National Institutes of Health stroke scale（NIHSS）. Changes of neural function were studied. Results The total effective rate of urinary kallidinogenase group was 89. 58% . The total effective rate of control group was 77. 08%. The total effective rate of urinary kallidinogenase group was significantly higher than that of control group after 14 days of treatment. There was significant difference between the two groups （P 〈 0. 05）. There were no adverse reactions in the two groups. Conclusions Urinary kallidinogenase combined with batroxobin is effective and safe in treatment of the patients with acute cerebral infarction, so it is worthy to be popularized in clinics.